This product is delipidated during its purification process from human plasma. Although it is not routinely tested for final lipid contamination, previous lots have been tested by SPIFE Vis Cholesterol Gel against a cholesterol profile standard and no visible lipid contamination had been found.
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
0.5 MG
€ 419,00
1 MG
€ 723,00
Über diesen Artikel
Fortfahren mit
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenbiological source
human plasma
assay
≥85% (SDS-PAGE)
form
buffered aqueous solution
mol wt
28.3 kDa
technique(s)
ELISA: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... APOA1(335)
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Verwandte Kategorien
1 of 4
Dieser Artikel | |||
|---|---|---|---|
| assay ≥85% (SDS-PAGE) | assay ≥95% (SDS-PAGE) | assay ≥95% (SDS-GE) | assay ≥95% (SDS-PAGE) |
| technique(s) ELISA: suitable | technique(s) - | technique(s) electrophoresis: suitable | technique(s) - |
| biological source human plasma | biological source human plasma | biological source human plasma | biological source - |
| form buffered aqueous solution | form buffered aqueous solution | form buffered aqueous solution | form liquid |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| shipped in dry ice | shipped in dry ice | shipped in - | shipped in wet ice |
Application
Apolipoprotein A-I from human plasma has been used to induce cholesterol efflux in nitrobenzoxadiazole (NBD)-cholesterol loaded cells. It has also been used to detect IgG anti-apoA-1 antibodies using enzyme linked immunosorbent assay (ELISA).
Major protein components in high density lipoprotein (HDL)
Biochem/physiol Actions
Activates lecithin-cholesterol acyltransferase (LCAT), which is responsible for cholesterol esterification in plasma.
Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of α-helix structure. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Physical form
Solution in 10 mM ammonium bicarbonate
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Lagerklasse
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Gantsetseg Tumurkhuu et al.
Cell metabolism, 28(3), 432-448 (2018-06-26)
Pathogen burden accelerates atherosclerosis, but the mechanisms remain unresolved. Activation of the NLRP3 inflammasome is linked to atherogenesis. Here we investigated whether Chlamydia pneumoniae (C.pn) infection engages NLRP3 in promoting atherosclerosis. C.pn potentiated hyperlipidemia-induced inflammasome activity in cultured macrophages and
Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals
Lagerstedt JO, et al.
Journal of Internal Medicine, 285(1), 49-58 (2019)
J O Lagerstedt et al.
Journal of internal medicine, 285(1), 49-58 (2018-07-22)
IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively
IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study
Croca S, et al.
Arthritis Research & Therapy, 17(1), 26-26 (2015)
H J Menzel et al.
The Journal of biological chemistry, 259(5), 3070-3076 (1984-03-10)
Variant forms of apolipoprotein A-I (apo-A-I) have been shown to exist in the human population. One mutant form, referred to as apo-A-I-Münster-3, is one charge unit more basic than normal apo-A-I on isoelectric focusing gels. This variant has the same
Artikel
Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.
Verwandter Inhalt
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A0722-.5MG | 04061833334317 |
| A0722-1MG | 04061833334324 |
-
Is Product No. A0722, ApoA1 delipidated?
1 answer-
Helpful?
-
Active Filters
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung